创新医疗(002173.SZ)：博灵脑机产品赛博灵科AC5已于2025年10月正式上市销售

Core Viewpoint - Innovation Medical (002173.SZ) has experienced significant stock price fluctuations, with a cumulative increase of over 20% in three consecutive trading days, indicating market interest in its brain-computer interface business [1] Group 1: Company Overview - Innovation Medical's subsidiary, Boling Brain Technology (Hangzhou) Co., Ltd., was established in early 2021 and included in the consolidated financial statements in August 2025 [1] - The primary products of Boling Brain Technology are designed for rehabilitation training of patients with cerebrovascular diseases, mainly focusing on stroke and hemiplegia [1] Group 2: Product and Financial Performance - The product "Cyberlink AC5" was officially launched in October 2025, generating revenue of 114,000 yuan in that year [1] - The "Cyberlink AM5" has completed multi-center clinical trials but has not generated revenue in 2025 [1] - Boling Brain Technology reported operating losses of 6.60 million yuan in 2023 and 8.66 million yuan in 2024 [1]